E2 Antibody

What are E2 antibodies and which biological targets do they recognize?

E2 antibodies target different proteins designated as "E2" across biological systems:

• Cyclin E2: A cell cycle regulator involved in cellular proliferation and cancer development. Human Cyclin E2 antibodies like MAB7444 are generated using E. coli-derived recombinant human Cyclin E2 (Met1-Gln140) .

• Viral envelope proteins: Including the E2 glycoprotein of HCV (Hepatitis C Virus) and the E2 protein of CSFV (Classical Swine Fever Virus) .

Antibody specificity depends on the immunogen used for generation and requires thorough validation for the target of interest.

What research applications benefit most from E2 antibody use?

E2 antibodies serve multiple research functions:

• Immunohistochemistry (IHC): Localizing E2 proteins in tissue sections, such as Cyclin E2 in cervical cancer tissue .

• ELISA: Quantitative detection of antibodies against E2 proteins in serum samples for viral infection diagnosis .

• Neutralization assays: Evaluating antibody-mediated viral neutralization capabilities .

• Immunochromatographic test strips (ICS): Rapid detection of antibodies in field conditions for disease surveillance .

• Western blotting: Analyzing E2 protein expression in cell and tissue lysates.

• Immunoprecipitation: Studying protein-protein interactions involving E2 proteins.

How do E2 antibodies function in viral immunology research?

E2 antibodies play crucial roles in understanding viral immunology:

• They identify epitope landscapes on viral proteins such as the SARS-CoV-2 spike protein .

• They help classify antibody communities with distinct footprints and competition profiles in receptor binding domains .

• They enable monitoring of antibody responses in infected or vaccinated subjects .

• They facilitate the development of DIVA (Differentiating Infected from Vaccinated Animals) strategies for disease control .

• They contribute to understanding viral escape mechanisms through studies of variant-resistant epitopes .

What storage and handling protocols optimize E2 antibody performance?

Proper handling significantly impacts antibody functionality:

• Long-term storage: Maintain at -20 to -70°C for up to 12 months from receipt date .

• After reconstitution: Store at 2-8°C under sterile conditions for up to 1 month, or at -20 to -70°C for up to 6 months .

• Freeze-thaw cycles: Use manual defrost freezers and minimize freeze-thaw cycles to preserve activity .

• Working concentrations: Titrate for each application; for example, 1.2 μg/mL for IHC of Cyclin E2 in human tissues .

What validation steps should precede using a new E2 antibody in experimental systems?

Comprehensive validation should include:

• Positive and negative controls: Confirm specificity using known positive and negative samples.

• Cross-reactivity assessment: Test against related proteins to establish specificity.

• Species cross-reactivity testing: Verify functionality across species if working with multiple animal models .

• Titration experiments: Determine optimal working concentrations for each application.

• Application-specific validation: Confirm functionality in each intended application (IHC, ELISA, Western blot, etc.).

• Epitope mapping: Understand which specific regions of the target protein the antibody recognizes.

How can you optimize E2 antibody-based immunohistochemistry protocols?

For optimal IHC performance:

• Fixation optimization: Determine ideal fixation conditions that preserve epitope accessibility.

• Antigen retrieval: Cyclin E2 detection in paraffin-embedded tissues benefits from appropriate antigen retrieval methods .

• Concentration optimization: Titrate antibody concentration (e.g., 1.2 μg/mL for Cyclin E2 in cervical cancer tissue) .

• Incubation conditions: For some applications, overnight incubation at 4°C improves signal-to-noise ratio .

• Detection system selection: Choose appropriate detection systems like HRP-DAB for colorimetric visualization .

• Counterstaining: Use hematoxylin for nuclear visualization when examining nuclear proteins like Cyclin E2 .

How can computational design improve E2 antibody cross-reactivity across species?

Computational approaches can enhance antibody functionality:

• In silico design strategies: Modify protein-protein interactions to improve binding across species .

• Energy function analysis: Molecular mechanics-based energy functions with implicit solvent models predict mutation effects at protease-antibody interfaces .

• Free energy calculations: Programs like the Protein Local Optimization Program (PLOP) calculate changes in binding free energy upon mutation (ΔΔGmut) .

• Interface residue identification: Select residues within 5Å of differing amino acids between species for targeted mutation .

• Homology modeling: Create structural models when crystal structures are unavailable to guide rational design .

• Rotamer optimization: Optimize side chain conformations during computational modeling to improve accuracy .

How are E2 antibodies used in epitope mapping and variant analysis?

E2 antibodies are instrumental in understanding epitope landscapes:

• Epitope consortium approaches: International collaborations map epitope landscapes on viral proteins like SARS-CoV-2 spike protein .

• Antibody classification: Define distinct antibody communities with specific footprints and competition profiles .

• Mutation impact assessment: Pseudovirion-based neutralization assays reveal how individual mutations affect antibody function .

• Variant resistance evaluation: Identify antibody classes that maintain neutralization activity against emerging viral variants .

• Treatment cocktail development: These findings provide frameworks for selecting antibody treatment combinations .

What are the key considerations when designing E2 antibody-based diagnostic tests?

Diagnostic test development requires methodological rigor:

• Precision testing: Evaluate variation coefficients for within-run (typically 6-9%) and between-run (10-14%) tests .

• Detection limit determination: Establish blank limits and detection limits (e.g., 1.18-3.16 RLIR for anti-E1 and 1.26-3.32 RLIR for anti-E2) .

• Linear range assessment: Define analysis and measurement ranges (AMR) for quantitative applications .

• Interference testing: Evaluate potential interference from rheumatoid factors and cross-reactive antigens .

• Stability analysis: Assess long-term stability (e.g., 15 months for some assays) .

• Clinical validation: Test with relevant patient populations to determine clinical sensitivity and specificity .

How should researchers address inconsistencies between different E2 antibody detection methods?

When faced with discrepant results:

• Method comparison: Different detection platforms (ELISA vs. ICS) may have varying sensitivities and specificities. For example, E2 antibody detection showed agreement rates of 93.0-96.5% between ICS and commercial ELISA kits .

• Timing considerations: Antibody detection thresholds vary by method and time post-infection/vaccination. E2 antibodies may require different timeframes to reach detection thresholds compared to neutralization tests .

• Gold standard comparisons: Use neutralization tests as reference standards when evaluating new assays .

• Agreement rate calculation: Determine the percentage of concordant results between methods to quantify reliability .

• Analytical sensitivity vs. clinical relevance: Higher analytical sensitivity doesn't always translate to greater clinical utility.

What factors affect E2 antibody specificity in experimental systems?

Several factors influence specificity:

• Antibody generation method: Monoclonal vs. polyclonal approaches affect specificity profiles.

• Target protein conformation: Native vs. denatured states may expose different epitopes.

• Buffer conditions: pH, salt concentration, and detergents can alter binding characteristics.

• Cross-reactive proteins: Structurally similar proteins may bind antibodies non-specifically.

• Post-translational modifications: Modifications can create or mask epitopes.

• Species differences: Amino acid variations between species affect binding even in conserved proteins .

How can researchers distinguish between E2 antibody signals in dual infection/vaccination scenarios?

Advanced discrimination techniques include:

• Dual-antibody detection systems: ICS can simultaneously detect antibodies against multiple viral components (E2 and Erns) .

• DIVA strategies: Compare antibody profiles between chimeric vaccine recipients and naturally infected animals .

• Temporal analysis: Monitor antibody development patterns over time, as different antibodies develop at different rates post-infection/vaccination .

• Epitope-specific assays: Design tests targeting epitopes present only in wild-type viruses but not in vaccine strains .

• Comparative serology: Use multiple test formats to build comprehensive antibody profiles .

How are E2 antibodies contributing to DIVA vaccine development?

DIVA approaches leverage differential antibody responses:

• Chimeric vaccine design: Vaccines like vGPE−/PAPeV Erns and vGPE−/PhoPeV Erns induce E2 antibodies without generating Erns antibodies .

• Dual-detection platforms: ICS systems simultaneously detect E2 and Erns antibodies, enabling differentiation between vaccinated and infected animals .

• Temporal monitoring: Long-term antibody monitoring in vaccinated animals reveals differential response patterns .

• Challenge studies: Controlled infection studies after vaccination confirm DIVA capability of chimeric vaccines .

• Field application: Rapid diagnostic tools for detecting antibodies against CSFV support disease surveillance programs .

What methodological advancements are improving E2 antibody detection systems?

Recent technological improvements include:

• Chemiluminescence methods: Novel approaches for detecting anti-E1 and anti-E2 antibodies in HCV infection with high sensitivity .

• Recombinant protein coating: Direct coating of microplates with recombinant envelope proteins improves assay performance .

• Multiplex testing: Simultaneous detection of multiple antibodies reduces time and resource requirements .

• Rapid field diagnostics: ICS development permits point-of-need testing without laboratory infrastructure .

• Plant-derived antigens: E2 and Erns antigens derived from plants show potential for engineering dual-antibody detection systems .

How are E2 antibodies facilitating understanding of immune responses in viral infections?

E2 antibodies provide valuable insights into immunology:

• Immune response mapping: In HCV infection, detection rates of 44.4% for anti-E2 antibodies help characterize patient immune responses .

• Viral variant analysis: Studies of variant-resistant epitopes targeted by antibodies guide therapeutic development .

• Epitope competition: Understanding how antibodies compete for binding sites informs vaccine design .

• Neutralization mechanisms: Analysis of RBD-directed antibody communities illuminates mechanisms of viral neutralization .

• Therapeutic antibody development: Mapping epitope landscapes supports the development of antibody cocktails resistant to viral escape .